Nature Milestone: Cancer
Exploring key breakthroughs in cancer
Published
These Milestones celebrate two decades of breakthroughs in basic, translational and clinical research which have revolutionised our understanding and management of cancer. This Milestone:
- Explores the first identified mechanisms of resistance to targeted treatments.
- Reports on the first trial to show that a bivalent vaccine for HPVs 16 and 18 could reduce cervical cancer risk.
- Highlights the papers that reported that defects in BRCA1 or BRCA2 are synthetically lethal with loss of PARP function.
- Explores the first whole-genome sequence of a cancer.
- Reports on the first papers to show mutations in histones in paediatric high-grade gliomas.
- Describes the landmark discovery that the gut microbiome is a modulator of response to cancer therapies.
View the interactive timeline >>
View the Collection of papers >>
Nature Portfolio is pleased to acknowledge financial support from Illumina, Inc, Johnson & Johnson and grant support from AstraZeneca, Boehringer Ingelheim International GmbH, and Merck & Co., Inc., Kenilworth, NJ, USA in producing this Nature Milestone.
No comments yet.